Breast Cancer-targets And Therapy

Breast Cancer-targets And Therapy

乳腺癌-靶点和治疗

  • 4区 中科院分区
  • Q2 JCR分区

期刊简介

《Breast Cancer-targets And Therapy》是由Dove Medical Press出版社创办的英文国际期刊(ISSN: 1179-1314,E-ISSN: 1179-1314),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为ONCOLOGY。作为SCIE收录期刊(JCR分区 Q2,中科院 4区),本刊采用OA开放获取模式(OA占比1%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比77.33%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在75篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Breast Cancer-targets And Therapy审稿周期约为 16 Weeks 。该刊近年未被列入国际预警名单,年发文量约75篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 75 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 118 / 322

63.5%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 186 / 322

42.39%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:4.1 SJR:0.933 SNIP:1.009
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q3 203 / 404

49%

期刊发文

  • Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques

    Author: Zhang, Quanbin; Zeng, Yu; Peng, Yingying; Yu, Hui; Zhang, Shuxu; Wu, Shuyu

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 25-38. DOI: 10.2147/BCTT.S383369

  • An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC

    Author: Zhang, Mengqi; Bao, Shengxian; Qiu, Guanhua; Liang, Jingchen; Wang, Qin; Zhu, Xiaoqi; Qin, Guchun; Liu, Junjie; Zhao, Chang

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 101-119. DOI: 10.2147/BCTT.S387793

  • Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review

    Author: Wu, Jing; Jin, Yudi; Liu, Mei; Zhu, Ningsheng; Jing, Zhouhong; Zeng, Xiaohua

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 39-45. DOI: 10.2147/BCTT.S395944

  • Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

    Author: Wang, Jin; Liao, Dongying; Zhang, Xuemin; Miao, Changhong; Chen, Kuang

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 281-294. DOI: 10.2147/BCTT.S407181

  • Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients

    Author: Shen, Jun; Yan, Huanhuan; Yang, Congying; Lin, Haiyue; Li, Fan; Zhou, Jun

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 295-310. DOI: 10.2147/BCTT.S402109

  • Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins

    Author: Ma, Jing; Dong, Chao; Cao, Yan-Zhen; Ma, Bin-Lin

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 11-24. DOI: 10.2147/BCTT.S390017

  • The Prognostic Role of HuR Varies Between Different Subtypes of Breast Cancer Patients: Data Mining and Retrospective Analysis

    Author: Liao, Yuqian; Liao, Yulu; Li, Jun; Li, Yong; Fan, Ying

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 135-146. DOI: 10.2147/BCTT.S395984

  • Optimized Radiomics Nomogram Based on Automated Breast Ultrasound System: A Potential Tool for Preoperative Prediction of Metastatic Lymph Node Burden in Breast Cancer

    Author: Li, Ning; Song, Chao; Huang, Xian; Zhang, Hongjiang; Su, Juan; Yang, Lichun; He, Juhua; Cui, Guihua

    Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 121-132. DOI: 10.2147/BCTT.S398300